TABLE 1.
Patient demographics
| Characteristic | Surgery (N = 40) |
Embolization (N = 33) |
p value* |
|---|---|---|---|
| Age, years, median (range) | 65.5 (26–78) | 71 (31–91) | .04 |
| Sex | .55 | ||
| Male | 6 (15 %) | 7 (21 %) | |
| Female | 34 (85 %) | 26 (79 %) | |
| Okuda stage | .0004 | ||
| 1 | 40 (100 %) | 24 (73 %) | |
| 2 | 0 (0 %) | 9 (27 %) | |
| Modified BCLC stage** | .43 | ||
| 0 | 1 (2 %) | 1 (3 %) | |
| A1 | 16 (40 %) | 16 (48 %) | |
| A2 | 2 (5 %) | 4 (12 %) | |
| B | 21 (53 %) | 12 (36 %) | |
| Childs–Pugh class | .04 | ||
| A | 39 (100 %) | 29 (88 %) | |
| B | 0 (0 %) | 4 (12 %) | |
| NA | 1 | ||
| Tumor size, median (range) | 5 (1.8–6.8) | 3.8 (1.7–7) | .05 |
| ≤3 cm | 7 (18 %) | 11 (33 %) | |
| 3.1–4.2 cm | 9 (22 %) | 9 (27 %) | |
| 4.3–5.5 cm | 12 (30 %) | 7 (21 %) | |
| 5.6–7 cm | 12 (30 %) | 6 (18 %) |
*
Fisher exact or Wilcoxon rank sum test
**
Modified BCLC stage incorporates the data available retrospectively, including Child Pugh score, serum bilirubin and presence/absence of portal hypertension. Functional status, a key component of BCLC stage was not available for all patients and was not included